Analytical Data
-
基因名
SGCd
- Application
-
别名
35DAG; CMD1L; DAGD; SG-delta; SGCDP; SGD; 35kDa Dystrophin-Associated Glycoprotein
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q92629
-
表达区间
Ile63~Leu289
-
分子量
28kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCd (Sarcoglycan delta) is a member of the sarcoglycan family, which plays a crucial role in the integrity and stability of the muscle cell membrane, particularly in skeletal and cardiac muscles. Mutations in the SGCd gene are associated with various muscular dystrophies, including limb-girdle muscular dystrophy (LGMD). Given the significant impact of these disorders on patient quality of life, there is a pressing need for effective therapies. Research into SGCd recombinant proteins focuses on understanding its structure, function, and interactions within the muscle membrane complex. Scientists aim to develop gene therapies or protein replacement strategies that can restore normal SGCd function in affected muscle tissues. Furthermore, studying SGCd's role in cellular signaling and muscle repair mechanisms can provide insights into potential therapeutic targets. Advances in recombinant protein technology enable the production of functional SGCd for use in preclinical models, paving the way for potential clinical applications. As research continues, SGCd reconstruction holds promise not only for treating LGMD but also for broader applications in muscular dystrophies and associated muscle disorders.
